Dare Bioscience Announces Return Of Rights To Ovaprene Phase 3 Program Ongoing Positive Interim Data
RefinitivOkuma süresi: 1 dakikadan kısa
Dare Bioscience Inc 
DARE:
DARÉ BIOSCIENCE ANNOUNCES RETURN OF RIGHTS TO OVAPRENE®; PHASE 3 PROGRAM ONGOING; POSITIVE INTERIM DATA AND GRANT FUNDING POSITION ASSET FOR VALUE-MAXIMIZATION
DARE BIOSCIENCE INC - TERMINATION EFFECTIVE FEBRUARY 2026, DARÉ GAINS FULL CONTROL OF OVAPRENE
© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html
Bu haberi okumak için giriş yapın veya sonsuza kadar ücretsiz bir hesap oluşturun